Table 3.

Premature study termination and deaths

Patients with a 12-month observation period (SAF) [n (%)]	39 (11.5%)
Patients with premature study termination after start of treatment, i.e. observation period < 12 months (SAF) [n (%)]	292 (86.4%)
Patients alive at study termination and with data available (SAF)	130
Main reasons for premature study termination (SAF) [n (%)]:
Tumor progression	74 (56.9%)
Patient’s wish	21 (16.2%)
Physician’s decision	13 (10.0%)
Absent rash	9 (6.9%)
Withdrawal of informed consent	2 (1.5%)
Lost to follow-up	2 (1.5%)
Toxicity of erlotinib	1 (0.8%)
Toxicity of gemcitabine	1 (0.8%)
Other	7 (5.4%)
Patients who started a second/further-line treatment and were alive at premature termination (SAF) [n (%)]	43 (33.1%)
Deaths before regular study end (SAF)	133
Causes of death [n (%)]:
Tumor progression	84 (63.2%)
Pancreatic cancer	29 (21.8%)
Toxicity of gemcitabine	1 (0.8%)
Unknown	11 (8.3%)
Other	8 (6.0%)
Patients who were lost to follow-up (SAF) [n (%)]	29 8.6%)